Effect of Different Antitumor Regimens on Incidence and Severity of Corona Virus
Disease 2019 Pneumonia in Lung Cancer Patients:
A Single-center Retrospective Study.
10.3779/j.issn.1009-3419.2023.102.20
- Author:
Wanjun LU
1
;
Jiawen LV
1
;
Qin WANG
2
;
Yanwen YAO
2
;
Dong WANG
2
;
Jiayan CHEN
3
;
Guannan WU
2
;
Xiaoling GU
2
;
Huijuan LI
2
;
Yajuan CHEN
2
;
Hedong HAN
2
;
Tangfeng LV
1
;
Yong SONG
1
;
Ping ZHAN
1
Author Information
1. Department of Respiratory and Critical Care, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, China.
2. Department of Respiratory and Critical Care, General Hospital of Eastern Theater Command, People's Liberation Army of China, Nanjing 210002, China.
3. Department of Respiratory and Critical Care, Jinling Hospital, Nanjing Medical University, Nanjing 210002, China.
- Publication Type:Journal Article
- Keywords:
Antitumor treatment;
Corona virus disease 2019;
Lung neoplasms
- MeSH:
Humans;
COVID-19;
Retrospective Studies;
Lung Neoplasms/drug therapy*;
Incidence;
Pneumonia/etiology*
- From:
Chinese Journal of Lung Cancer
2023;26(6):429-438
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Studies have shown that the incidence and severity of corona virus disease 2019 (COVID-19) in patients with lung cancer are higher than those in healthy people. At present, the main anti-tumor treatments for lung cancer include surgery, immunotherapy, chemotherapy, radiotherapy, targeted therapy and anti-angiogenesis therapy. While the effects of different anti-tumor treatments on the occurrence and severity of COVID-19 pneumonia are not uniform. Therefore, we aimed to describe clinical characteristics and antitumor therapy of patients with lung cancer and COVID-19 pneumonia, and examined risk factors for severity in this population.
METHODS:From December 1, 2022 to February 15, 2023, a retrospective study was conducted in 217 patients diagnosed with COVID-19 and pathologically confirmed lung cancer in the Jinling Hospital. We collected data about patients' clinical features, antitumor treatment regimen within 6 months, and the diagnosis and treatment of COVID-19. Risk factors for occurrence and severity of COVID-19 pneumonia were identified by univariable and multivariable Logistic regression models.
RESULTS:(1) Among the 217 patients included, 51 (23.5%) developed COVID-19 pneumonia, of which 42 (82.4%) were classified as medium and 9 (17.6%) were classified as severe; (2) Univariate and multivariate analysis revealed overweight (OR=2.405, 95%CI: 1.095-5.286) and intrapulmonary focal radiotherapy (OR=2.977, 95%CI: 1.071-8.274) are risk factors for increasing occurrence of COVID-19 pneumonia, while other therapies are not; (3) Chronic obstructive pulmonary disease (COPD) history (OR=7.600, 95%CI: 1.430-40.387) was more likely to develop severe pneumonia and anti-tumor therapies such as intrapulmonary focal radiotherapy, chemotherapy, targeted therapy and immunotherapy did not increase severity.
CONCLUSIONS:Intrapulmonary focal radiation therapy within 6 months increased the incidence of COVID-19 pneumonia, but did not increase the severity. However, there was no safety concern for chemotherapy, targeted therapy, surgery and immunotherapy.
